Abstract
Aims/hypothesis
Diabetic macular oedema (DME) is the leading cause of visual impairment in people with diabetes. Intravitreal injections of vascular endothelial growth factor inhibitors or corticosteroids prevent loss of vision by reducing DME, but the injections must be given frequently and usually for years. Here we report laboratory and clinical studies on the safety and efficacy of 670 nm photobiomodulation (PBM) for treatment of centre-involving DME.
Methods
The therapeutic effect of PBM delivered via a light-emitting diode (LED) device was tested in transgenic mice in which induced Müller cell disruption led to photoreceptor degeneration and retinal vascular leakage. We also developed a purpose-built 670 nm retinal laser for PBM to treat DME in humans. The effect of laser-delivered PBM on improving mitochondrial function and protecting against oxidative stress was studied in cultured rat Müller cells and its safety was studied in pigmented and non-pigmented rat eyes. We then used the retinal laser to perform PBM in an open-label, dose-escalation Phase IIa clinical trial involving 21 patients with centre-involving DME. Patients received 12 sessions of PBM over 5 weeks for 90 s per treatment at a setting of 25, 100 or 200 mW/cm2 for the three sequential cohorts of 6–8 patients each. Patients were recruited from the Sydney Eye Hospital, over the age of 18 and had centre-involving DME with central macular thickness (CMT) of >300 μm with visual acuity of 75–35 Log minimum angle of resolution (logMAR) letters (Snellen visual acuity equivalent of 20/30–20/200). The objective of this trial was to assess the safety and efficacy of laser-delivered PBM at 2 and 6 months. The primary efficacy outcome was change in CMT at 2 and 6 months.
Results
LED-delivered PBM enhanced photoreceptor mitochondrial membrane potential, protected Müller cells and photoreceptors from damage and reduced retinal vascular leakage resulting from induced Müller cell disruption in transgenic mice. PBM delivered via the retinal laser enhanced mitochondrial function and protected against oxidative stress in cultured Müller cells. Laser-delivered PBM did not damage the retina in pigmented rat eyes at 100 mW/cm2. The completed clinical trial found a significant reduction in CMT at 2 months by 59 ± 46 μm (p = 0.03 at 200 mW/cm2) and significant reduction at all three settings at 6 months (25 mW/cm2: 53 ± 24 μm, p = 0.04; 100 mW/cm2: 129 ± 51 μm, p < 0.01; 200 mW/cm2: 114 ± 60 μm, p < 0.01). Laser-delivered PBM was well tolerated in humans at settings up to 200 mW/cm2 with no significant side effects.
Conclusions/interpretation
PBM results in anatomical improvement of DME over 6 months and may represent a safe and non-invasive treatment. Further testing is warranted in randomised clinical trials.
Trial registration
ClinicalTrials.gov NCT02181400
Similar content being viewed by others
Introduction
Diabetic macular oedema (DME), the leading cause of visual impairment in people with diabetes [1, 2], is characterised by accumulation of fluid in the macula due to breakdown of the blood retinal barrier (BRB). The inner BRB is formed by tight junctions between endothelial cells of retinal vessels [3, 4]. Hyperglycaemia results in oxidative stress, inflammation, and upregulation of vascular endothelial growth factor (VEGF), cytokines and chemokines, leading to breakdown of the BRB [3, 5]. This in turn results in fluid accumulation within the retina and eventually irreversible visual impairment from damage to photoreceptors [3].
Intravitreal injections of VEGF inhibitors are currently the first line treatment for DME [6, 7]. Anti-VEGF therapies can be extremely effective in treating vascular leakage, but they usually require many injections over several years before the disease stabilises. They may also be associated with uncommon but serious adverse effects, including endophthalmitis and a possible increased risk of myocardial infarction and cerebrovascular accidents [6,7,8]. Intravitreal injection of corticosteroids, generally reserved for second line treatment, is limited by their side effects of causing cataract and elevated intraocular pressure [6].
Photobiomodulation (PBM) has recently emerged as a potential treatment for a variety of neurological conditions [9, 10]. This technique involves exposure of tissue to a low intensity of light at wavelengths ranging from 600 nm to 1000 nm. The benefits of PBM for retinal diseases have been described in animal models of retinal conditions including age-related macular degeneration, retinopathy of prematurity and diabetic retinopathy [9, 11]. PBM has been reported to inhibit superoxide production and other aspects of local inflammation in the retina [11,12,13,14]. Previous studies indicated that a brief daily application of PBM at a wavelength of 670 nm through a light-emitting diode (LED) device inhibited the molecular processes implicated in diabetic retinopathy in rodents [13,14,15] and reduced retinal thickness in four patients with non-centre-involving DME [16].
Here we report laboratory and clinical studies of PBM for the treatment of DME. First, we studied the effects of LED-delivered PBM on protecting Müller cells and photoreceptors from damage and reducing retinal vascular leakage in transgenic mice with induced Müller cell disruption [17, 18]. Next, we developed a purpose-built 670 nm retinal laser for PBM and outline the mechanisms and protective effects of laser-delivered PBM in vitro. We have studied the safety of laser-delivered PBM in rats before testing it clinically. Last, we used the purpose-built retinal laser to treat 21 eyes with centre-involving DME in an open-label dose-escalation Phase IIa clinical trial.
Methods
Animals
Animal studies were approved by the institutional animal ethics committees and conform with the Association for Research in Vision and Ophthalmology (ARVO) statement for the Use of Animals in Ophthalmic and Vision Research. Transgenic mice for induced Müller cell disruption were generated as described previously [17,18,19]. Sprague Dawley rat pups and adults and Dark Agouti adult rats were also used in this study. Both male and female animals were used in this study. Mice in the same litter were randomly assigned based on their odd or even animal identification numbers for PBM or sham treatment. The experimenters were blind to outcome assessments. See electronic supplementary material (ESM) Methods for details.
LED-delivery PBM in transgenic mice
The effect of PBM on photoreceptor protection was studied immediately after induced Müller cell disruption (Fig. 1a). Briefly, after pupil dilation, a WARP10 LED device (Quantum Devices, Barneveld, WI, USA) was held 1 cm in front of the eyes of unsedated mice (ESM Fig. 1). Each mouse received two cycles of PBM per day for 9 days, with both eyes treated at 40 mW/cm2 for 90 s/cycle. Sham-treated mice were exposed to ambient light only. In order to study the effect of PBM on retinal vascular leakage, we performed fundus fluorescein angiography (FFA) to confirm vascular leakage 3 months after induced Müller cell disruption and then applied daily PBM or sham treatment for 9 days (Fig. 2a). Changes in vascular leakage was studied by FFA and quantitative analysis of retinal permeability to fluorescent dextran [17, 18, 20]. Transgenic mice that did not develop retinal vascular leakage at 3 months after intraperitoneal injections of tamoxifen were excluded from the leakage study. See ESM Methods.
Immunostaining using retinal wholemounts and frozen sections
Photoreceptor mitochondrial membrane potential was studied using the mitochondrial dye 5,5′,6,6′-tetrachloro-1,1′,3,3′ tetraethylbenzimidazolylcarbocyanine iodide (JC-1) as described previously [21]. Briefly, retinas were freshly prepared and incubated in pre-warmed neurobasal medium containing 25 μg/ml JC-1 (Invitrogen, Australia) for 45 min. After washing in PBS, retinas were fixed with 4% paraformaldehyde, counterstained with Hoechst 33342 and flatmounted with photoreceptor facing up for confocal fluorescent microscopy. We also performed peanut agglutinin (PNA) staining to study cone photoreceptor apical processes in fixed retinal wholemounts and immunostaining for glutamine synthetase (GS, Merck, Australia; #MAB302, 1:100) on frozen sections to study Müller cells as described previously [17,18,19]. Images from single plate confocal fluorescent microscopy were analysed using ImageJ [17,18,19].
Laser-delivered PBM system
As LED-delivered PBM emits non-coherent scattered irradiation, which may become a barrier to clinical translation, we developed a custom-designed, slit lamp microscope-mounted Integre retinal laser (Ellex Medical Lasers, Adelaide, Australia) to deliver precise PBM (ESM Fig. 2). This retinal laser emits a 670 nm laser beam with 4.5 mm diameter at a power density ranging from 25 to 500 mW/cm2.
Metabolic analysis and immunocytochemistry in Müller cells treated with laser-delivered PBM
Müller cells were isolated from 2–4-day-old rat pups as described previously [22]. Cultured cells were treated with PBM by placing plates on a warmed horizontal platform attached to the chin rest in the slit lamp retinal laser system (ESM Fig. 2). Treatments were applied centrally to individual wells at 100 mW/cm2 for 90 s. Cell respiratory activity was analysed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays [22]. The mitochondrial respiratory activity was further measured in detail using a Seahorse XFe96 extracellular flux analyser (Agilent Technologies Australia, Mulgrave, VIC, Australia). Alamar Blue cell viability assays were performed to study whether PBM protects Müller cells from injury. We performed immunocytochemistry using an antibody against vimentin (Dako, 1:5000) to study whether PBM alters Müller cell morphology. See ESM Methods for details.
Live cell imaging to assess mitochondrial respiratory activity
Sham- or laser PBM-treated cells were exposed to a medium containing 5 μmol/l MitoSOX Red dye (ThermoFisher Scientific, Scoresby, VIC, Australia) for 10 min. This dye is oxidised by superoxide production in the mitochondria of live cells to form a product that is highly fluorescent upon binding to nucleic acids. Cells were co-labelled with the MitoSOX Red fluorescence and the nuclear Hoechst dye 33,342 for confocal fluorescent microscopy. See ESM Methods.
Laser-delivered PBM in rats
The safety of laser-delivered PBM was studied in Sprague Dawley and Dark Agouti rats after treating retinas with 100 or 500 mW/cm2 every 2 days for 1 week. Spectral domain optical coherence tomography (SD-OCT) was performed concurrently with fundus imaging at baseline and 1 week after the last treatment. Eyes were enucleated and fixed for histology and immunostaining 1 week after the last PBM. See ESM Methods.
Human ethics approval, participants and treatments in clinical trial
The clinical study was approved by institutional human ethics committees and adhered to the tenets of the Declaration of Helsinki. All study participants were given informed consent. Twenty-one participants aged ≥18 years with DME and central macular thickness (CMT) >300 μm on SD-OCT and visual acuity of 75–35 Log minimum angle of resolution (logMAR) letters (Snellen visual acuity equivalent of 20/30–20/200) were allocated sequentially into three groups based on the power for PBM (Table 1). A total of 7, 6 and 8 participants were recruited into group 1 (25 mW/cm2), group 2 (100 mW/cm2) and group 3 (200 mW/cm2), respectively. We included a central masked area of 1.0 mm diameter within the 4.5 mm diameter treatment zone to spare the fovea. PBM was applied through a standard fundus contact lens with the patient fixating on the central aiming beam. Each patient received 12 sessions of PBM over 5 weeks. See ESM Methods.
Rescue treatment and study outcomes
Standard of care treatment for DME was allowed at the discretion of the treating physician. The primary endpoint to ascertain the efficacy of PBM was change in CMT from baseline to 2 and 6 months after treatment. Changes in CMT between groups at 2 and 6 months were also assessed. Secondary outcome measures included best corrected visual acuity (BCVA) 2 and 6 months after treatment and the proportion of eyes that received rescue treatment.
SD-OCT imaging in humans
SD-OCT images were obtained on the Spectralis/HRA2 OCT (Heidelberg Engineering, Heidelberg, Germany). CMT for the nine Early Treatment Diabetic Retinopathy Study (ETDRS) subfields was obtained from automated segmentation using the Heidelberg Eye Explorer software (version 6.9.5; Heidelberg Engineering).
Statistical analyses
Results from preclinical studies are expressed as mean ± SEM. Data were analysed using an unpaired two-tailed Student’s t test or ANOVA with a post hoc Tukey’s or Bonferroni’s correction for multiple comparisons. The sample size for the clinical study was based on a paired t test such that each of the three treatment groups had an 80% power to detect a change from baseline CMT of 100 μm with an SD of 50 μm at the 6 month time point with an α level set at 0.01 to allow for comparisons between groups to maintain the significance level within 0.05 when comparing groups to determine the most effective dosage. Descriptive data from clinical studies are presented as mean (95% CI), mean ± SD, median or number (percentage). Student’s t test, Wilcoxon rank sum and χ2 tests were used where appropriate to compare baseline characteristics between groups. A repeated ANCOVA model across repeated observations at month 2 and 6 with the baseline measures as a covariate was used. Last observation carried forward (LOCF) analysis was applied as the last measure prior to any additional treatment in addition to PBM therapy. Analyses were conducted using R V3.3.1 [23]. A p value <0.05 was regarded as statistically significant.
Results
Preclinical studies
LED-delivered PBM enhanced photoreceptor mitochondrial membrane potential and protected Müller cells and photoreceptors from injury
Photoreceptor mitochondrial membrane potential was studied by staining retinal wholemounts with the mitochondrial dye JC-1 (Fig. 1a–h). The cationic JC-1 dye shifts towards 525 nm (green) emission when the mitochondrial membrane depolarises, while increased membrane potential causes JC-1 monomers to form aggregates that shift the light emission towards 590 nm (red) [21, 24]. In transgenic mice receiving sham treatment, Müller cell disruption led to patchy loss of photoreceptor apical processes including the inner segments (Fig. 1b–d), while the surviving photoreceptor inner segments expressed strong green and weak red fluorescence after JC-1 staining, indicating a reduced mitochondrial membrane potential (Fig. 1b–d). PBM reduced the green fluorescence and increased red fluorescence at the photoreceptor inner segments, suggesting an enhanced mitochondrial membrane potential (Fig. 1e–g). Analysis of the ratio of red/green JC-1 fluorescence indicated that PBM had little effect on the mitochondrial membrane potential in wild-type mice (ESM Fig. 3) but significantly increased the ratio of red/green JC-1 fluorescence in transgenic mice (Fig. 1h).
We next studied whether PBM protects Müller cells and photoreceptors from injury (Fig. 1i–q). PBM did not affect the pattern of PNA staining in wild-type mice but attenuated the loss of cone apical processes in transgenic mice (Fig. 1i–l). Quantitative analysis indicated that the PNA-stained area was similar between PBM- and sham-treated eyes in wild-type mice but significantly larger in transgenic mice receiving PBM than sham-treated mice (Fig. 1m). Analysis of GS+ Müller cells indicated that the number of Müller cells was significantly reduced in transgenic mice receiving sham treatment compared with wild-type controls but the number of Müller cells in PBM-treated transgenic mice was significantly higher than that in the sham-treated group (Fig. 1n–q).
PBM reduced retinal vascular leakage in transgenic mice
We next studied the effect of LED-delivered PBM on retinal vascular leakage (Fig. 2a–h). PBM in wild type mice did not affect the integrity of the normal vasculature (Fig. 2b, c). Transgenic mice developed focal intense vascular leak 3 months after Müller cell disruption (Fig. 2d, f) and the vascular leak remained relatively unchanged during the study period (Fig. 2d, e). However, PBM reduced retinal vascular leakage revealed by FFA (Fig. 2f, g) and significantly decreased the extravasation of fluorescently labelled dextran (Fig. 2h).
Laser-delivered PBM enhanced mitochondrial function and protected Müller cells against oxidative stress
MTT assays indicated that cell metabolic activity was significantly increased immediately after PBM in Müller cells and it continued to rise for 24 h (Fig. 3a). Seahorse extracellular flux analysis indicated that PBM significantly increased the levels of basal and ATP-linked cellular respiration (Fig. 3b–d) while the maximum respiration remained unchanged (Fig. 3b, e). These effects were accompanied by reduced reserve respiratory capacity (Fig. 3f).
We performed AlamarBlue cell viability assays to study whether PBM protected Müller cells in vitro (Fig. 3g). The half-maximal response (EC50) to tert-butyl hydroperoxide (tBH)-induced cell injury was approximately 375 μmol/l in sham-treated rat Müller cells. PBM 24 h prior to tBH challenge elevated the EC50 of tBH to approximately 650 μmol/l. The number of viable Müller cells was significantly higher in the PBM-treated group than that in the sham-treated group after challenging cells with 500 μmol/l tBH for 24 h (Fig. 3g).
Laser-delivered PBM did not affect the basic cell morphology and enhanced mitochondrial respiratory activity in Müller cells
PBM delivered up to 500 mW/cm2 did not affect the Müller cell morphology (Fig. 4a). Cellular respiratory function was probed using MitoSOX Red (Fig. 4b, c). Immediately after PBM at 100 mW/cm2, incubating Müller cells with MitoSOX Red for 10 min revealed almost a complete co-localisation of red fluorescence with nuclear blue labelling, indicating a very strong activity in mitochondrial oxidative phosphorylation. The percentage of cell nuclei positive for MitoSOX Red decreased over time but was still significantly higher than the sham-treated group 24 h and 48 h after PBM (Fig. 4c). These results indicate that PBM increased Müller cell mitochondrial respiration.
Laser-delivered PBM had a defined safety profile in pigmented eyes
We studied the safety of laser-delivered PBM in pigmented and non-pigmented rat eyes. None of the pigmented eyes from sham- (n = 6, data not shown) or 100 mW/cm2 (n = 7) treated groups displayed any abnormalities on SD-OCT, fundus imaging, FFA or histology (Fig. 5a–i; ESM Fig. 4). However, by 7 days post PBM, 4 of 10 pigmented eyes treated with 500 mW/cm2 showed fundus and SD-OCT changes (Fig. 5j, k) although the retinal vasculature appeared normal (Fig. 5l). In the affected regions, the retinal thickness was reduced from 247.8 ± 11.0 μm to 166.8 ± 11.6 μm and the outer nuclear layer was essentially obliterated and not measurable by SD-OCT. Histological examination confirmed the findings from SD-OCT (Fig. 5d–i, m–r). PBM at 500 mW/cm2 did not damage non-pigmented retinas (data not shown).
Clinical studies
Baseline characteristics
There was no significant difference in baseline characteristics among the three groups treated with laser-delivered PBM at 25, 100 or 200 mW/cm2 (Table 1).
Primary outcome measures: changes in CMT
There was an overall reduction in CMT at month 2 and 6 with LOCF in eyes receiving rescue treatment. Changes in CMT were not significantly different between treatment groups at month 2. There was a significantly greater reduction in CMT in groups 2 (100 mW/cm2) and 3 (200 mW/cm2) than in group 1 (25 mW/cm2) at month 6 post treatment. Changes in CMT are summarised in Table 2 and Fig. 6a, b. Examples of various outcomes after PBM treatment are shown in Figs 7, 8, and 9.
Secondary outcome measures: changes in BCVA
The mean BCVA (SD) increased by 4.0 (7.1) logMAR letters (p = 0.02) from baseline to month 2. However, the overall visual acuity gain was not sustained at month 6 (p = 0.49). Changes in BCVA are summarised in Table 2 and Fig. 6c, d.
Rescue treatments
Rescue treatment was administered to five eyes that were deemed to have worsening DME at the physician’s discretion (3 eyes from group 1, 2 eyes from group 2 and none from group 3). All rescue treatments were administered 2 months post PBM, thus allowing the primary analysis to be carried out in all eyes. Six month outcomes were taken as LOCF prior to the rescue treatment. Of the three eyes receiving rescue treatment in group 1, two eyes were treated about 3 months from baseline (one eye was treated with bevacizumab and the other eye with focal laser), and one eye was treated with bevacizumab about 4 months from baseline. Of the two eyes receiving rescue treatment in group 2, one eye was treated with bevacizumab about 4 months from baseline, and the other eye was treated with dexamethasone implant about 5 months from baseline.
Safety
There were no adverse effects in eyes treated with laser-delivered PBM at 25, 100 or 200 mW/cm2 in our clinical study.
Discussion
We have evaluated the potential of PBM for treating DME. LED-delivered PBM enhanced photoreceptor mitochondrial membrane potential, prevented Müller cell loss and photoreceptor degeneration and reduced the retinal vascular leakage that resulted from induced Müller cell disruption. We next used a purpose-built retinal laser to treat 21 eyes affected by centre-involving DME. Laser-delivered PBM improved visual acuity and reduced CMT from 2 months after PBM, with a reduction in CMT that persisted for up to 6 months. Our results suggest that PBM may offer a safe non-invasive treatment for DME.
It is postulated that the beneficial effects of PBM are mediated through stimulation of cytochrome c oxidase on the electron transport chain [9, 10], enhancing mitochondrial membrane potential, increasing ATP synthesis [9, 10, 25] and decreasing the production of reactive oxygen species [10, 26]. Photoreceptor inner segments are rich in mitochondria [27, 28]. We found that Müller cell disruption led to decreased photoreceptor mitochondrial membrane potential, suggesting that mitochondrial dysfunction is one of the causes of the photoreceptor degeneration that follows Müller cell disruption. We also found that PBM enhanced the photoreceptor mitochondrial membrane potential and protected Müller cells and photoreceptors. These results are consistent with previous findings that PBM protects photoreceptors in animal models of light-induced photoreceptor injury [11, 29, 30], suggesting that PBM might be a way to protect photoreceptors from degeneration [3].
Since LED-delivered PBM emits non-coherent irradiation that may become a barrier to clinical translation, we next developed a 670 nm retinal laser to deliver precise PBM. We found that laser-delivered PBM enhanced metabolic activity, increased oxygen consumption rate (OCR), enhanced mitochondrial function and protected Müller cells against oxidative stress in vitro, further confirming our earlier finding that PBM protected Müller cells in our transgenic mice. The beneficial effects of PBM on protecting photoreceptors may involve multiple mechanisms. Lu et al reported that PBM reduced the expression of proinflammatory cytokines and decreased photoreceptor loss in light-induced photoreceptor degeneration [11]. Other potential mechanisms include stimulating expression of neurotrophic factors [31], decreasing production of reactive oxygen species [10, 26], regulating anti-apoptotic and pro-apoptotic mediators [32], suppressing inflammation [11, 30] and activating transcription factors to regulate gene expression [10, 33].
DME is characterised by fluid accumulation in the macula resulting from an imbalance in cellular fluid movement. Since there is no accessible animal model that replicates DME found in humans, we tested the effect of PBM on both the focal and diffuse vascular leakage that follows induced disruption of Müller cells [17, 19] and found that PBM reduced retinal vascular leakage. We acknowledge that focal intense vascular leakage in our transgenic mice is due to the development of intraretinal neovascularisation [17, 18, 20] rather than breakdown of the BRB. These transgenic mice may not be an exact model of DME in humans; however, the diffuse retinal vascular leakage that we quantitatively measured and found to be reduced by PBM is similar to the features of DME in humans.
Multiple mechanisms may account for the reduced retinal vascular leakage after PBM in transgenic mice with induced Müller cell disruption. We found that PBM protected Müller cells in vivo and in vitro. Improved Müller cell survival and function may attenuate retinal vascular leakage because Müller cells are involved in the formation of the inner BRB and regulation of retinal homeostasis [3, 11]. We previously found that patchy ablation of Müller cells led to activation of the remaining Müller cells and infiltration of microglia and macrophages [17,18,19,20]. Recent studies indicate that PBM inhibits Müller cell activation and reduces recruitment of microglia and macrophages, leading to decreased expression of proinflammatory cytokines including chemokine (C-C motif) ligand 2 (CCL2), IL-1β and IL-6 in light-induced photoreceptor degeneration [11, 12]. Upregulation of proinflammatory mediators is believed to actively contribute to breakdown of the BRB [3, 34]. We postulate that PBM may also inhibit retinal inflammation to improve the BRB in our transgenic mice. We have previously reported that the retinal vascular abnormalities resulting from Müller cell disruption were associated with overexpression of VEGF and proinflammatory cytokines [17,18,19,20, 35, 36] along with reduced tight junction protein claudin-5 [17]. Future research is warranted to use an extensive approach, such as RNA-sequencing analysis, to study the effects of PBM on differential expression of angiogenic factors, proinflammatory mediators and tight junction proteins in our transgenic mice.
We studied the safety of laser-delivered PBM in rat eyes before testing it clinically. There are occasional reports about the adverse effects of near-infrared laser at higher power settings. Application of an 808 nm diode laser transcranial to the brain cortex of rats up to 375 mW/cm2 appeared safe, but tissue damage was observed at 750 mW/cm2 [37]. With 500 mW/cm2, we found no adverse effects in non-pigmented eyes but observed localised photoreceptor damage in some pigmented eyes. The underlying mechanism is unknown, but a photothermal response is most likely [38]. Based on the safety study in rats, we included two measures to reduce the risk of adverse events in clinical study: first, a central masked area of 1 mm diameter was incorporated within the 4.5 mm diameter treatment zone to spare the fovea; second, the maximum dosage for PBM was 200 mW/cm2. No significant adverse events were observed in the clinical study.
The major finding from the clinical study was that laser-delivered PBM resulted in dose-dependent and long-term (6 months) reductions in CMT of eyes with centre-involving DME. As this was a single arm non-randomised pilot study, an objective primary outcome measure, change in CMT, was chosen to prevent any placebo effect that may occur from subjective measures such as visual acuity.
The groups receiving PBM at 100 or 200 mW/cm2 had greater reduction in CMT than eyes receiving 25 mW/cm2 6 months post treatment, which was comparable to the reduction in CMT in eyes treated with conventional laser photocoagulation for DME [39,40,41] and slightly less than the reduction in CMT after monthly intravitreal injections of ranibizumab [40]. No eyes treated with the highest dose, 200 mW/cm2, required rescue treatment throughout the course of the trial. Few other clinical trials have reported the clinical effects of PBM on DME, with most of the literature focused on in vitro and animal disease models [13, 14, 42]. A previous study using LED-delivered PBM in four patients with non-centre-involving DME [16] reported a similar reduction in macular thickness to what we observed.
Overall, there was only a small increase in visual acuity after 2 months, which was not sustained at 6 months. This may be due to lack of power to detect a difference rather than a real finding. The generally good starting vision, average of about 65–70 logMAR letters (Snellen equivalent of 6/15–6/12) of eyes in this study, is also likely to have placed a ‘ceiling’ on vision gains [43].
A strength of the clinical study is that PBM was administered via a retinal laser in a standardised way by specialist ophthalmologists. One limitation of our clinical study was the small number of patients enrolled which did not provide enough power to assess change in BCVA as a primary outcome. Another limitation was the lack of standardised criteria for the administration of rescue standard of care, which was left to the discretion of the treating physicians. Questions that need addressing in future studies are whether PBM can be used as an adjunct therapy to improve the effectiveness and reduce the frequency of intravitreal injections of VEGF inhibitors, and how often PBM should be applied.
In conclusion, our preclinical studies indicate that PBM is effective in improving mitochondrial function in photoreceptors and Müller cells. PBM protected Müller cell loss and photoreceptor degeneration and reduced retinal vascular leakage resulting from induced Müller cell disruption. An open-label Phase IIa clinical trial suggested that laser-delivered PBM is a safe and potentially effective treatment for DME. Further investigation of PBM for DME is warranted with a larger, randomised, controlled, Phase II study, such as the one currently being conducted by the Diabetic Retinopathy Collaborative Research network (clinicaltrials.gov identifier: NCT03866473). Additional positive studies would lay the foundation for a definitive Phase III randomised controlled trial.
Data availability
The datasets generated from the current study are available from the corresponding authors upon reasonable request. No applicable resources were generated or analysed during the current study.
Abbreviations
- BCVA:
-
Best corrected visual acuity
- BRB:
-
Blood retinal barrier
- CMT:
-
Central macular thickness
- DME:
-
Diabetic macular oedema
- EC50 :
-
Half-maximal response
- ETDRS:
-
Early Treatment Diabetic Retinopathy Study
- FFA:
-
Fundus fluorescein angiography
- GS:
-
Glutamine synthetase
- JC-1:
-
5,5′,6,6′-Tetrachloro-1,1′,3,3′ tetraethylbenzimi-dazolylcarbocyanine iodide
- LED:
-
Light-emitting diode
- LOCF:
-
Last observation carried forward
- LogMAR:
-
Log minimum angle of resolution
- MTT:
-
3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
- OCR:
-
Oxygen consumption rate
- PBM:
-
Photobiomodulation
- PNA:
-
Peanut agglutinin
- SD-OCT:
-
Spectral domain optical coherence tomography
- tBH:
-
tert-Butyl hydroperoxide
- VEGF:
-
Vascular endothelial growth factor
References
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91(12):1464–1474
Holekamp NM (2016) Overview of diabetic macular edema. Am J Manag Care 22(10 Suppl):s284–s291
Daruich A, Matet A, Moulin A et al (2018) Mechanisms of macular edema: beyond the surface. Prog Retin Eye Res 63:20–68. https://doi.org/10.1016/j.preteyeres.2017.10.006
Vecino E, Rodriguez FD, Ruzafa N, Pereiro X, Sharma SC (2016) Glia-neuron interactions in the mammalian retina. Prog Retin Eye Res 51:1–40. https://doi.org/10.1016/j.preteyeres.2015.06.003
Spaide RF (2016) Retinal vascular cystoid macular edema: review and new theory. Retina 36(10):1823–1842. https://doi.org/10.1097/IAE.0000000000001158
He Y, Ren XJ, Hu BJ, Lam WC, Li XR (2018) A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema. BMC Ophthalmol 18(1):121. https://doi.org/10.1186/s12886-018-0779-1
Xu Y, Tan CS (2017) Safety and complications of intravitreal injections performed in an Asian population in Singapore. Int Ophthalmol 37(2):325–332. https://doi.org/10.1007/s10792-016-0241-4
Falavarjani KG, Nguyen QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 27(7):787–794. https://doi.org/10.1038/eye.2013.107
Geneva, II (2016) Photobiomodulation for the treatment of retinal diseases: a review. Int J Ophthalmol 9(1):145–152. https://doi.org/10.18240/ijo.2016.01.24
Salehpour F, Mahmoudi J, Kamari F et al (2018) Brain photobiomodulation therapy: a narrative review. Mol Neurobiol 55(8):6601–6636. https://doi.org/10.1007/s12035-017-0852-4
Lu YZ, Fernando N, Natoli R, Madigan M, Valter K (2018) 670nm light treatment following retinal injury modulates Muller cell gliosis: evidence from in vivo and in vitro stress models. Exp Eye Res 169:1–12. https://doi.org/10.1016/j.exer.2018.01.011
Lu YZ, Natoli R, Madigan M et al (2017) Photobiomodulation with 670 nm light ameliorates Muller cell-mediated activation of microglia and macrophages in retinal degeneration. Exp Eye Res 165:78–89. https://doi.org/10.1016/j.exer.2017.09.002
Saliba A, Du Y, Liu H et al (2015) Photobiomodulation mitigates diabetes-induced retinopathy by direct and indirect mechanisms: evidence from intervention studies in pigmented mice. PLoS One 10(10):e0139003. https://doi.org/10.1371/journal.pone.0139003
Tang J, Du Y, Lee CA et al (2013) Low-intensity far-red light inhibits early lesions that contribute to diabetic retinopathy: in vivo and in vitro. Invest Ophthalmol Vis Sci 54(5):3681–3690. https://doi.org/10.1167/iovs.12-11018
Cheng Y, Du Y, Liu H et al (2018) Photobiomodulation inhibits long-term structural and functional lesions of diabetic retinopathy. Diabetes 67(2):291–298. https://doi.org/10.2337/db17-0803
Tang J, Herda AA, Kern TS (2014) Photobiomodulation in the treatment of patients with non-center-involving diabetic macular oedema. Br J Ophthalmol 98(8):1013–1015. https://doi.org/10.1136/bjophthalmol-2013-304477
Shen W, Fruttiger M, Zhu L et al (2012) Conditional Müller cell ablation causes independent neuronal and vascular pathologies in a novel transgenic model. J Neurosci 32(45):15715–15727. https://doi.org/10.1523/JNEUROSCI.2841-12.2012
Shen W, Lee SR, Araujo J et al (2014) Effect of glucocorticoids on neuronal and vascular pathology in a transgenic model of selective Muller cell ablation. Glia 62(7):1110–1124. https://doi.org/10.1002/glia.22666
Shen W, Zhu L, Lee SR, Chung SH, Gillies MC (2013) Involvement of NT3 and P75(NTR) in photoreceptor degeneration following selective Muller cell ablation. J Neuroinflammation 10:137. https://doi.org/10.1186/1742-2094-10-137
Shen W, Lee SR, Yam M et al (2018) A combination therapy targeting endoglin and VEGF-A prevents subretinal fibro-neovascularization caused by induced Muller cell disruption. Invest Ophthalmol Vis Sci 59(15):6075–6088. https://doi.org/10.1167/iovs.18-25628
Roehlecke C, Schumann U, Ader M et al (2013) Stress reaction in outer segments of photoreceptors after blue light irradiation. PLoS One 8(9):e71570. https://doi.org/10.1371/journal.pone.0071570
Wood JP, Mammone T, Chidlow G, Greenwell T, Casson RJ (2012) Mitochondrial inhibition in rat retinal cell cultures as a model of metabolic compromise: mechanisms of injury and neuroprotection. Invest Ophthalmol Vis Sci 53(8):4897–4909. https://doi.org/10.1167/iovs.11-9171
R Development Core Team (2017) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
Kokkinopoulos I, Colman A, Hogg C, Heckenlively J, Jeffery G (2013) Age-related retinal inflammation is reduced by 670 nm light via increased mitochondrial membrane potential. Neurobiol Aging 34(2):602–609. https://doi.org/10.1016/j.neurobiolaging.2012.04.014
Hamblin MR (2018) Mechanisms and mitochondrial redox signaling in photobiomodulation. Photochem Photobiol 94(2):199–212. https://doi.org/10.1111/php.12864
Salehpour F, Ahmadian N, Rasta SH et al (2017) Transcranial low-level laser therapy improves brain mitochondrial function and cognitive impairment in D-galactose-induced aging mice. Neurobiol Aging 58:140–150. https://doi.org/10.1016/j.neurobiolaging.2017.06.025
Litts KM, Zhang Y, Freund KB, Curcio CA (2018) Optical coherence tomography and histology of age-related macular degeneration support mitochondria as reflectivity sources. Retina 38(3):445–461. https://doi.org/10.1097/IAE.0000000000001946
Xie W, Zhao M, Tsai SH et al (2018) Correlation of spectral domain optical coherence tomography with histology and electron microscopy in the porcine retina. Exp Eye Res 177:181–190. https://doi.org/10.1016/j.exer.2018.08.003
Qu C, Cao W, Fan Y, Lin Y (2010) Near-infrared light protect the photoreceptor from light-induced damage in rats. Adv Exp Med Biol 664:365–374. https://doi.org/10.1007/978-1-4419-1399-9_42
Albarracin R, Eells J, Valter K (2011) Photobiomodulation protects the retina from light-induced photoreceptor degeneration. Invest Ophthalmol Vis Sci 52(6):3582–3592. https://doi.org/10.1167/iovs.10-6664
Zhang J, Liu R, Kuang HY, Gao XY, Liu HL (2017) Protective treatments and their target retinal ganglion cells in diabetic retinopathy. Brain Res Bull 132:53–60. https://doi.org/10.1016/j.brainresbull.2017.05.007
Wang R, Dong Y, Lu Y et al (2018) Photobiomodulation for global cerebral ischemia: targeting mitochondrial dynamics and functions. Mol Neurobiol. https://doi.org/10.1007/s12035-018-1191-9
Jere SW, Houreld NN, Abrahamse H (2018) Photobiomodulation at 660nm stimulates proliferation and migration of diabetic wounded cells via the expression of epidermal growth factor and the JAK/STAT pathway. J Photochem Photobiol B 179:74–83. https://doi.org/10.1016/j.jphotobiol.2017.12.026
Mesquida M, Drawnel F, Fauser S (2019) The role of inflammation in diabetic eye disease. Semin Immunopathol 41(4):427–445. https://doi.org/10.1007/s00281-019-00750-7
Chung SH, Gillies M, Sugiyama Y et al (2015) Profiling of microRNAs involved in retinal degeneration caused by selective Muller cell ablation. PLoS One 10(3):e0118949. https://doi.org/10.1371/journal.pone.0118949
Chung SH, Gillies M, Yam M, Wang Y, Shen W (2016) Differential expression of microRNAs in retinal vasculopathy caused by selective Muller cell disruption. Sci Rep 6:28993. https://doi.org/10.1038/srep28993
Ilic S, Leichliter S, Streeter J et al (2006) Effects of power densities, continuous and pulse frequencies, and number of sessions of low-level laser therapy on intact rat brain. Photomed Laser Surg 24(4):458–466. https://doi.org/10.1089/pho.2006.24.458
Youssef PN, Sheibani N, Albert DM (2011) Retinal light toxicity. Eye (Lond) 25(1):1–14. https://doi.org/10.1038/eye.2010.149
Do DV, Schmidt-Erfurth U, Gonzalez VH et al (2011) The DA VINCI study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema. Ophthalmology 118(9):1819–1826
Nguyen QD, Shah SM, Khwaja AA et al (2010) Two-year outcomes of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 117(11):2146–2151
Mitchell P, Bandello F, Schmidt-Erfurth U et al (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118(4):615–625
Eells JT, Gopalakrishnan S, Valter K (2016) Near-infrared photobiomodulation in retinal injury and disease. Adv Exp Med Biol 854:437–441
Sophie R, Lu N, Campochiaro PA (2015) Predictors of functional and anatomic outcomes in patients with diabetic macular edema treated with ranibizumab. Ophthalmology 122(7):1395–1401. https://doi.org/10.1016/j.ophtha.2015.02.036
Funding
Preclinical studies were supported by grants from National Health and Medical Research Council of Australia (NH&MRC, APP1028393) and the Ophthalmic Research Institute of Australia. The clinical trials were supported by grants from the Sydney Eye Hospital Foundation and Australian Federal Government Innovation Connections. MCG is supported by Sydney Medical School Foundation and an NH&MRC Practitioner Fellowship (APP1103406). KYCT and EEC were supported by fellowships from Sydney Eye Hospital Foundation with funding from Bayer and Novartis. The study sponsors were not involved in the design of the study; the collection, analysis and interpretation of data; or writing the report and did not impose any restrictions regarding the publication of the report.
Author information
Authors and Affiliations
Contributions
WS, JPMW and GC designed laboratory studies. RJC and MCG designed clinical studies. WS, KYCT, JPMW, GC, JA, AV, EEC, SRL, MXY and SFB performed research, and analysed and interpreted data. WS, KYCT, JPMW, GC, RJC and MCG wrote the paper. All authors have reviewed the final version of the manuscript and approved it to be published. MCG and RJC are the guarantors of this work and, as such, had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Corresponding authors
Ethics declarations
MCG has relevant financial activities with Novartis, Allergan, Roche and Bayer. The remaining authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM
(PDF 787 kb)
Rights and permissions
About this article
Cite this article
Shen, W., Teo, K.Y.C., Wood, J.P.M. et al. Preclinical and clinical studies of photobiomodulation therapy for macular oedema. Diabetologia 63, 1900–1915 (2020). https://doi.org/10.1007/s00125-020-05189-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00125-020-05189-2